Salvage HDR brachytherapy delayed systemic therapy after isolated seminal vesicle recurrence
In 22 patients, salvage HDR brachytherapy produced 40.5% five-year relapse-free survival but 18% developed grade ≥3 GU toxicity.
In 22 patients, salvage HDR brachytherapy produced 40.5% five-year relapse-free survival but 18% developed grade ≥3 GU toxicity.
In MDT-BRIDGE, patients who became unresectable during neoadjuvant durvalumab plus chemotherapy could transition to definitive CRT and consolidation durvalumab, with 85% 12-month PFS in a small selected cohort.
In phase II LipCap, liposomal irinotecan plus capecitabine with long-course chemoradiotherapy produced a 21.7% overall complete response rate in LARC, with grade 3-4 toxicity in 16.7%. Long-term efficacy remains unknown.
Nearly three in ten surveyed cervical cancer survivors reported partial-to-probable PTSD symptoms several years after HDR brachytherapy.
Sequential chemotherapy plus five-fraction SBRT produced 86.7% one-year local control with 7.7% acute grade 3 toxicity in STARLORD.
Multimodal LLM prediction reached an AUC of 0.79, but AI-generated MRI reports showed clinically important discordances requiring expert review.
Control, predictability, information and relational continuity emerged as key needs for making awake pediatric proton therapy more manageable.
In a small ESTRO poll, subjective and lower-grade adverse events showed substantial disagreement despite shared CTCAE v6.0 definitions.
A simple counting task added about 19 seconds to prolonged DIBH in breast cancer patients after oxygenation and hyperventilation.
Normal-lung CT response was partly reproducible across RT courses, while short retreatment intervals increased response in previously irradiated lung.
One patient underwent 21 Gy in three fractions to 44 recurrent brain metastases after WBRT, with rapid delivery and sustained local control.
Postoperative bowel dysfunction correlated most strongly with high-dose exposure to the internal anal sphincter and puborectalis complex.
Prednisone 3 mg/kg improved symptoms in 3 of 5 survivors with late cranial neuropathy, but the benefit disappeared by 6–10 weeks.
In one rapidly enlarging cranial Masson’s tumor, 54 Gy in 27 fractions halted growth and enabled subsequent necrosectomy.
Two prostate RT cases suggest that focal lumbosacral plexus hotspots, particularly near 70 Gy, may contribute to severe neurologic toxicity.